TRPV1 Epitope Antibodies for Selective Capsaicin Pain Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments targeting TRPV1 for pain relief, such as small molecule antagonists, cause adverse effects like hyperthermia and loss of heat sensation due to their inability to selectively inhibit capsaicin-induced activation without affecting heat-induced activation.
Innovation Solution
Identification and use of specific epitopes on the TRPV1 protein to generate antibodies that preferentially inhibit capsaicin-induced activation while minimizing heat-induced activation, using isolated peptides corresponding to these epitopes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule antagonists are used to block TRPV1, then pain relief is achieved, but adverse effects such as hyperthermia and loss of heat sensation occur due to non-selective inhibition
Solution Approach 1:
The patent applies segmentation by identifying and targeting specific epitopes (distinct regions) on the TRPV1 protein rather than using non-specific small molecule antagonists. By segmenting the TRPV1 protein into identifiable epitopic regions and generating antibodies against specific ones, the invention achieves selective inhibition of capsaicin-induced activation while preserving heat-induced activation, thereby avoiding hyperthermia and loss of heat sensation.
Solution Approach 2:
The patent applies local quality by creating antibodies with different binding specificities to different epitopes on TRPV1. Certain epitopes are associated with capsaicin activation while others are associated with heat activation. By selecting antibodies that bind preferentially to capsaicin-associated epitopes, the invention achieves localized functional inhibition at specific sites on the protein, preserving overall protein function for heat sensation while blocking pain pathways.
2Reliability
If antibodies are generated to inhibit TRPV1 activation, then capsaicin-induced activity is reduced, but heat-induced activation is also inhibited causing thermal side effects
Solution Approach 1:
The patent applies inversion by reversing the conventional approach: instead of trying to block all TRPV1 activation and accepting thermal side effects, the invention identifies and targets only the specific epitopic regions associated with capsaicin activation. This inverted strategy blocks pain pathways while deliberately preserving heat sensation pathways, achieving pain relief without thermal side effects.
Solution Approach 2:
The patent applies parameter changes by modifying the binding characteristics of antibodies to achieve differential inhibition. By selecting antibodies with specific binding affinities and epitopic specificities, the invention changes the parameters of TRPV1 inhibition to preferentially block capsaicin-induced activation while allowing heat-induced activation to proceed, thereby eliminating thermal side effects.
3Productivity
If non-specific TRPV1 antagonists are used, then broad inhibition of TRPV1 occurs, but inability to distinguish between capsaicin and heat activation pathways results
Solution Approach 1:
The patent applies segmentation by dividing the TRPV1 protein into distinct epitopic regions that are differentially involved in capsaicin versus heat activation. By generating antibodies against specific segmented epitopes rather than using non-specific antagonists, the invention achieves both high inhibition efficacy for capsaicin pathways and high selectivity, avoiding broad non-specific inhibition.
Data Source
AI summary
The present invention relates to antibodies that bind to TRPV1. The invention also relates to certain epitopes of the protein TRPV1. The invention also relates to immunoconjugates and compositions comprising such antibodies. The invention also provides methods of producing such antibodies. The invention further provides the use of such antibodies for therapeutic purposes, for example in the treatment of pain.